Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 12/20 | 0.51 |
| ▸ | THRB | P10828 | 12/20 | 0.51 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23003807 | 0.90 | THRB (0.60) | THRATHRBPELI1CSNK2A1SERPINE1 | |
| SCHEMBL23003627 | 0.90 | THRA (0.49) | THRATHRBPELI1CSNK2A1SERPINE1 | |
| SCHEMBL25528706 | 0.84 | THRA (0.57) | THRATHRBUSP2ALDH1A1HPGD | |
| SCHEMBL25528687 | 0.84 | THRB (0.50) | THRATHRB | |
| SCHEMBL25528576 | 0.82 | THRA (0.53) | THRATHRBUSP2ALDH1A1HPGD | |
| SCHEMBL25528562 | 0.82 | THRA (0.52) | THRATHRB | |
| SCHEMBL25528584 | 0.81 | THRB (0.49) | THRATHRBMCL1ALDH1A1HPGD | |
| SCHEMBL25528523 | 0.81 | THRA (0.51) | THRATHRB | |
| SCHEMBL25528580 | 0.81 | THRB (0.51) | THRATHRB | |
| SCHEMBL25528579 | 0.81 | THRA (0.51) | THRATHRBPELI1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667606-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667606-B2 | Thyromimetics | TPO, TSHR, TTR | THRA 4/4885THRB 9/4885PELI1 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.